Dabigatran
- Generic Name
- Dabigatran
- Brand Names
- Dabigatran Etexilate Leon Farma, Dabigatran Etexilate Accord, Pradaxa
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N7O3
- CAS Number
- 211914-51-1
- Unique Ingredient Identifier
- I0VM4M70GC
- Background
Dabigatran is the active form of the orally bioavailable prodrug dabigatran etexilate.
Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
- First Posted Date
- 2010-06-30
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 167
- Registration Number
- NCT01153698
- Locations
- 🇦🇹
1160.118.43007 Boehringer Ingelheim Investigational Site, Wien, Austria
🇦🇹1160.118.43004 Boehringer Ingelheim Investigational Site, Braunau, Austria
🇦🇹1160.118.43016 Boehringer Ingelheim Investigational Site, Stolzalpe, Austria
Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention
- Conditions
- Heart Catheterization
- Interventions
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT00818753
- Locations
- 🇳🇱
1160.73.31003 Boehringer Ingelheim Investigational Site, Nieuwegein, Netherlands
🇳🇱1160.73.31002 Boehringer Ingelheim Investigational Site, Rotterdam, Netherlands
🇳🇱1160.73.31004 Boehringer Ingelheim Investigational Site, Alkmaar, Netherlands
RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2008-12-15
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 5897
- Registration Number
- NCT00808067
- Locations
- 🇺🇸
1160.71.0119 Boehringer Ingelheim Investigational Site, Tupelo, Mississippi, United States
🇺🇸1160.71.0038 Boehringer Ingelheim Investigational Site, Hot Springs, Arkansas, United States
🇺🇸1160.71.0482 Boehringer Ingelheim Investigational Site, Guilford, Connecticut, United States
Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: matching placebo twice daily (BID)
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2014-06-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1353
- Registration Number
- NCT00558259
- Locations
- 🇺🇸
1160.63.01002 Boehringer Ingelheim Investigational Site, Laguna Hills, California, United States
🇺🇸1160.63.01020 Boehringer Ingelheim Investigational Site, Spartanburg, South Carolina, United States
🇺🇸1160.63.01032 Boehringer Ingelheim Investigational Site, Columbus, Ohio, United States
Secondary Prevention of Venous Thrombo Embolism (VTE).
- First Posted Date
- 2006-05-24
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2867
- Registration Number
- NCT00329238
- Locations
- 🇺🇸
1160.47.01030 Boehringer Ingelheim Investigational Site, Grand Forks, North Dakota, United States
🇨🇦1160.47.02019 Boehringer Ingelheim Investigational Site, Toronto, Ontario, Canada
🇲🇽1160.47.52030 Boehringer Ingelheim Investigational Site, Guadalajara, Jal., Mexico
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
- Conditions
- Thromboembolism
- Interventions
- First Posted Date
- 2006-02-14
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2564
- Registration Number
- NCT00291330
- Locations
- 🇺🇸
1160.53.01033 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States
🇺🇸1160.53.01046 Boehringer Ingelheim Investigational Site, Sarasota, Florida, United States
🇺🇸1160.53.01010 Boehringer Ingelheim Investigational Site, Marietta, Georgia, United States
Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate
- Conditions
- Atrial FibrillationStroke
- Interventions
- First Posted Date
- 2005-12-07
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18113
- Registration Number
- NCT00262600
- Locations
- 🇸🇪
1160.26.1633 Sahlgrenska Sjukhuset, Göteboerg, Sweden
🇺🇸1160.26.0278 Boehringer Ingelheim Investigational Site, Bridgeport, Connecticut, United States
🇺🇸1160.26.0358 Boehringer Ingelheim Investigational Site, Melbourne, Florida, United States
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
- Conditions
- Arthroplasty, Replacement, KneeThromboembolism
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2615
- Registration Number
- NCT00152971
- Locations
- 🇲🇽
1160.24.05009 Traumatologia, Planta Baja, Guadalajara, Jalisco, Mexico
🇺🇸1160.24.01010 MIMA Century Research Associates, Melbourne, Florida, United States
🇺🇸1160.24.01033 Bone and Joint Clinic of Houston, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.